The human report
Epithalamin and the elderly follow-up
The preparation, the comparison and the temptation of a confident title.
The people and the preparation
The human follow-up concerned 266 elderly people observed for 6-8 years. It involved the pineal peptide Epithalamin, alone and in combination with thymalin. The title makes an expansive claim about prolonging human life. The study design asks for a more measured conclusion.
The long follow-up was the collection's strongest attraction for me at first. Years of observation feel closer to the longevity question than a dish of cells. Then the particulars reasserted themselves: the comparison was observational, without randomisation or placebo control.
That is a reason to examine the association carefully. The time spent observing people adds information, while the design determines how confidently the outcome can be attributed to the preparation.
The reported mortality association
For Epithalamin alone, the entry reports a 1.6-1.8-fold mortality decrease versus untreated controls. It also includes combined treatment with thymalin. The preparation and the untreated comparison group are essential to the meaning of that association.
An observational comparison can describe what happened to the groups. Random allocation would address a different question: whether the groups' starting differences could account for some of the outcome. A placebo-controlled design would address another source of ambiguity. Here, the cited report's design leaves those causal questions open.
To me, a long follow-up and a strong causal inference are separate attractions. The years drew me into the paper. The latter would require a stronger comparison than the one described in this entry.
Epithalamin and Epitalon
This human report concerns Epithalamin. The normal and breast-cancer cell experiment concerns Epitalon. The review addresses Epitalon as an AEDG tetrapeptide. I regard the identity of the preparation as essential to any claim borrowed from these papers.
The similarity of the names makes it tempting to let the human follow-up settle the appeal of the cell findings. That leap asks me to discard too much of each experiment. The study populations, preparations and outcomes are stated separately in the entries, and the confidence of a title cannot bridge those differences.
A controlled human comparison with an unambiguous preparation and clearly specified outcomes would interest me enormously. The existing follow-up supplies a reason to ask for such work. I leave this paper wanting a controlled comparison of Epitalon itself before drawing a conclusion about a person's lifespan.